AsheshBJaniMD

Radiation Oncology • Atlanta, GA

Professor, Radiation Oncology, Emory University School of Medicine

Join to view full profile

Dr. Jani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Jani's full profile

Already have an account?

Office
1365 Clifton Rd Ne
Ste A1300
Atlanta, GA 30322
Phone+1 404-778-3827

Education & Training

University of Chicago/University of Illinois College of Medicine at ChicagoResidency, Radiation Oncology, 1996 - 2000
Rush University Medical CenterInternship, Internal Medicine, 1995 - 1996
University of Illinois College of MedicineClass of 1995

Certifications & Licensure

IL State Medical License 2000 - 2026
GA State Medical License 2006 - 2025
American Board of Radiology Radiation Oncology

Clinical Trials

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery Start of enrollment: 2008 Dec 01
Completed
Phase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Active, not recruiting
Phase 3
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
FACBC Outcomes for Post Prostatectomy Start of enrollment: 2012 Sep 01
Completed
Phase 2, Phase 3
Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes Start of enrollment: 2019 May 10
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Diuresis DuringF-Flotufolastat (rhPSMA-7.3) PET/CT Improves Recurrence Detection After Prostatectomy: A Prospective Phase II Trial.
Ismaheel O Lawal, Aliza Mushtaq, Ashesh B Jani, Manali Rupji, Vishal R Dhere
Journal of Nuclear Medicine. 2025-02-03
1 citations
Cross-shaped windows transformer with self-supervised pretraining for clinically significant prostate cancer detection in bi-parametric MRI.
Yuheng Li, Jacob Wynne, Jing Wang, Richard L J Qiu, Justin Roper
Medical Physics. 2025-02-01
Characteristics, Treatment, and Outcomes of Primary Urethral Cancer: A Multicenter Review Over Two Decades.
Benjamin D Hopkins, David C Qian, Karen M Xu, Ashley McCook-Veal, Jeffrey Switchenko
Clinical Genitourinary Cancer. 2025-02-01

Journal Articles

Analysis of Radiation Facility Volume and Survival in Men with Lymph Node–Positive Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy
Pretesh R Patel, Sheela Hanasoge, Vishal R Dhere, Karen D Godette, Ashesh B Jani, Bruce Hershatter, JAMA Network Open

Press Mentions

Blue Earth Diagnostics Announces Axumin® (Fluciclovine F 18) Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual MeetingJune 8th, 2021
Fluciclovine PET Tracer Improves Recurrent Prostate Cancer Treatment PlanningOctober 30th, 2020
Telix Pharmaceuticals and Emory Winship Cancer Institute to Collaborate on Clinical Trial Using Advanced Imaging of Prostate Cancer for RadiotherapyMay 30th, 2019
Join now to see all